TY - JOUR AU - Webster, R. M. PY - 2014 DA - 2014// TI - The immune checkpoint inhibitors: where are we now? JO - Nat Rev Drug Discov VL - 13 UR - https://doi.org/10.1038/nrd4476 DO - 10.1038/nrd4476 ID - Webster2014 ER - TY - JOUR AU - Wolchok, J. D. AU - Hoos, A. AU - O'Day, S. AU - Weber, J. S. AU - Hamid, O. AU - Lebbe, C. PY - 2009 DA - 2009// TI - Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1624 DO - 10.1158/1078-0432.CCR-09-1624 ID - Wolchok2009 ER - TY - JOUR AU - Hodi, F. S. AU - Hwu, W. J. AU - Kefford, R. AU - Weber, J. S. AU - Daud, A. AU - Hamid, O. PY - 2016 DA - 2016// TI - Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.0391 DO - 10.1200/JCO.2015.64.0391 ID - Hodi2016 ER - TY - JOUR AU - Postow, M. A. AU - Chesney, J. AU - Pavlick, A. C. AU - Robert, C. AU - Grossmann, K. AU - McDermott, D. PY - 2015 DA - 2015// TI - Nivolumab and ipilimumab versus ipilimumab in untreated melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1414428 DO - 10.1056/NEJMoa1414428 ID - Postow2015 ER - TY - JOUR AU - Garon, E. B. AU - Rizvi, N. A. AU - Hui, R. AU - Leighl, N. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2015 DA - 2015// TI - Pembrolizumab for the treatment of non-small-cell lung cancer JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1501824 DO - 10.1056/NEJMoa1501824 ID - Garon2015 ER - TY - JOUR AU - Smith, A. D. AU - Roda, D. AU - Yap, T. A. PY - 2014 DA - 2014// TI - Strategies for modern biomarker and drug development in oncology JO - J Hematol Oncol VL - 7 UR - https://doi.org/10.1186/s13045-014-0070-8 DO - 10.1186/s13045-014-0070-8 ID - Smith2014 ER - TY - JOUR AU - Pico de Coana, Y. AU - Choudhury, A. AU - Kiessling, R. PY - 2015 DA - 2015// TI - Checkpoint blockade for cancer therapy: revitalizing a suppressed immune system JO - Trends Mol Med VL - 21 UR - https://doi.org/10.1016/j.molmed.2015.05.005 DO - 10.1016/j.molmed.2015.05.005 ID - Pico de Coana2015 ER - TY - JOUR AU - Sharma, P. AU - Allison, J. P. PY - 2015 DA - 2015// TI - Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential JO - Cell VL - 161 UR - https://doi.org/10.1016/j.cell.2015.03.030 DO - 10.1016/j.cell.2015.03.030 ID - Sharma2015 ER - TY - JOUR AU - Ruffell, B. AU - Coussens, L. M. PY - 2015 DA - 2015// TI - Macrophages and therapeutic resistance in cancer JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2015.02.015 DO - 10.1016/j.ccell.2015.02.015 ID - Ruffell2015 ER - TY - JOUR AU - Coffelt, S. B. AU - Visser, K. E. PY - 2015 DA - 2015// TI - Immune-mediated mechanisms influencing the efficacy of anticancer therapies JO - Trends Immunol VL - 36 UR - https://doi.org/10.1016/j.it.2015.02.006 DO - 10.1016/j.it.2015.02.006 ID - Coffelt2015 ER - TY - JOUR AU - Woo, S. R. AU - Corrales, L. AU - Gajewski, T. F. PY - 2015 DA - 2015// TI - The STING pathway and the T cell-inflamed tumor microenvironment JO - Trends Immunol VL - 36 UR - https://doi.org/10.1016/j.it.2015.02.003 DO - 10.1016/j.it.2015.02.003 ID - Woo2015 ER - TY - JOUR AU - Goel, G. AU - Sun, W. PY - 2015 DA - 2015// TI - Advances in the management of gastrointestinal cancers—an upcoming role of immune checkpoint blockade JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0185-6 DO - 10.1186/s13045-015-0185-6 ID - Goel2015 ER - TY - JOUR AU - Chen, D. S. AU - Irving, B. A. AU - Hodi, F. S. PY - 2012 DA - 2012// TI - Molecular pathways: next-generation immunotherapy—inhibiting programmed death-ligand 1 and programmed death-1 JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1362 DO - 10.1158/1078-0432.CCR-12-1362 ID - Chen2012 ER - TY - JOUR AU - Topalian, S. L. AU - Weiner, G. J. AU - Pardoll, D. M. PY - 2011 DA - 2011// TI - Cancer immunotherapy comes of age JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2011.38.0899 DO - 10.1200/JCO.2011.38.0899 ID - Topalian2011 ER - TY - JOUR AU - Dunn, G. P. AU - Old, L. J. AU - Schreiber, R. D. PY - 2004 DA - 2004// TI - The three Es of cancer immunoediting JO - Annu Rev Immunol VL - 22 UR - https://doi.org/10.1146/annurev.immunol.22.012703.104803 DO - 10.1146/annurev.immunol.22.012703.104803 ID - Dunn2004 ER - TY - JOUR AU - Hacohen, N. AU - Fritsch, E. F. AU - Carter, T. A. AU - Lander, E. S. AU - Wu, C. J. PY - 2013 DA - 2013// TI - Getting personal with neoantigen-based therapeutic cancer vaccines JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0022 DO - 10.1158/2326-6066.CIR-13-0022 ID - Hacohen2013 ER - TY - JOUR AU - Kim, R. AU - Emi, M. AU - Tanabe, K. PY - 2007 DA - 2007// TI - Cancer immunoediting from immune surveillance to immune escape JO - Immunology VL - 121 UR - https://doi.org/10.1111/j.1365-2567.2007.02587.x DO - 10.1111/j.1365-2567.2007.02587.x ID - Kim2007 ER - TY - JOUR AU - Stewart, T. J. AU - Abrams, S. I. PY - 2008 DA - 2008// TI - How tumours escape mass destruction JO - Oncogene VL - 27 UR - https://doi.org/10.1038/onc.2008.268 DO - 10.1038/onc.2008.268 ID - Stewart2008 ER - TY - JOUR AU - Terme, M. AU - Pernot, S. AU - Marcheteau, E. AU - Sandoval, F. AU - Benhamouda, N. AU - Colussi, O. PY - 2013 DA - 2013// TI - VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer JO - Cancer Res VL - 73 UR - https://doi.org/10.1158/0008-5472.CAN-12-2325 DO - 10.1158/0008-5472.CAN-12-2325 ID - Terme2013 ER - TY - JOUR AU - Barber, D. L. AU - Wherry, E. J. AU - Masopust, D. AU - Zhu, B. AU - Allison, J. P. AU - Sharpe, A. H. PY - 2006 DA - 2006// TI - Restoring function in exhausted CD8 T cells during chronic viral infection JO - Nature VL - 439 UR - https://doi.org/10.1038/nature04444 DO - 10.1038/nature04444 ID - Barber2006 ER - TY - JOUR AU - Kim, P. S. AU - Ahmed, R. PY - 2010 DA - 2010// TI - Features of responding T cells in cancer and chronic infection JO - Curr Opin Immunol VL - 22 UR - https://doi.org/10.1016/j.coi.2010.02.005 DO - 10.1016/j.coi.2010.02.005 ID - Kim2010 ER - TY - JOUR AU - Bertrand, A. AU - Kostine, M. AU - Barnetche, T. AU - Truchetet, M. E. AU - Schaeverbeke, T. PY - 2015 DA - 2015// TI - Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis JO - BMC Med VL - 13 UR - https://doi.org/10.1186/s12916-015-0455-8 DO - 10.1186/s12916-015-0455-8 ID - Bertrand2015 ER - TY - JOUR AU - Corsello, S. M. AU - Barnabei, A. AU - Marchetti, P. AU - Vecchis, L. AU - Salvatori, R. AU - Torino, F. PY - 2013 DA - 2013// TI - Endocrine side effects induced by immune checkpoint inhibitors JO - J Clin Endocrinol Metab VL - 98 UR - https://doi.org/10.1210/jc.2012-4075 DO - 10.1210/jc.2012-4075 ID - Corsello2013 ER - TY - JOUR AU - Johnson, D. B. AU - Sullivan, R. J. AU - Ott, P. A. AU - Carlino, M. S. AU - Khushalani, N. I. AU - Ye, F. PY - 2016 DA - 2016// TI - Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2015.4368 DO - 10.1001/jamaoncol.2015.4368 ID - Johnson2016 ER - TY - JOUR AU - Keir, M. E. AU - Butte, M. J. AU - Freeman, G. J. AU - Sharpe, A. H. PY - 2008 DA - 2008// TI - PD-1 and its ligands in tolerance and immunity JO - Annu Rev Immunol VL - 26 UR - https://doi.org/10.1146/annurev.immunol.26.021607.090331 DO - 10.1146/annurev.immunol.26.021607.090331 ID - Keir2008 ER - TY - JOUR AU - Dorfman, D. M. AU - Brown, J. A. AU - Shahsafaei, A. AU - Freeman, G. J. PY - 2006 DA - 2006// TI - Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma JO - Am J Surg Pathol VL - 30 UR - https://doi.org/10.1097/01.pas.0000209855.28282.ce DO - 10.1097/01.pas.0000209855.28282.ce ID - Dorfman2006 ER - TY - JOUR AU - Ohaegbulam, K. C. AU - Assal, A. AU - Lazar-Molnar, E. AU - Yao, Y. AU - Zang, X. PY - 2015 DA - 2015// TI - Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway JO - Trends Mol Med VL - 21 UR - https://doi.org/10.1016/j.molmed.2014.10.009 DO - 10.1016/j.molmed.2014.10.009 ID - Ohaegbulam2015 ER - TY - JOUR AU - Yamazaki, T. AU - Akiba, H. AU - Iwai, H. AU - Matsuda, H. AU - Aoki, M. AU - Tanno, Y. PY - 2002 DA - 2002// TI - Expression of programmed death 1 ligands by murine T cells and APC JO - J Immunol VL - 169 UR - https://doi.org/10.4049/jimmunol.169.10.5538 DO - 10.4049/jimmunol.169.10.5538 ID - Yamazaki2002 ER - TY - JOUR AU - Eppihimer, M. J. AU - Gunn, J. AU - Freeman, G. J. AU - Greenfield, E. A. AU - Chernova, T. AU - Erickson, J. PY - 2002 DA - 2002// TI - Expression and regulation of the PD-L1 immunoinhibitory molecule on microvascular endothelial cells JO - Microcirculation VL - 9 UR - https://doi.org/10.1080/713774061 DO - 10.1080/713774061 ID - Eppihimer2002 ER - TY - JOUR AU - Schreiner, B. AU - Mitsdoerffer, M. AU - Kieseier, B. C. AU - Chen, L. AU - Hartung, H. P. AU - Weller, M. PY - 2004 DA - 2004// TI - Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis JO - J Neuroimmunol VL - 155 UR - https://doi.org/10.1016/j.jneuroim.2004.06.013 DO - 10.1016/j.jneuroim.2004.06.013 ID - Schreiner2004 ER - TY - JOUR AU - Formenti, S. C. AU - Demaria, S. PY - 2013 DA - 2013// TI - Combining radiotherapy and cancer immunotherapy: a paradigm shift JO - J Natl Cancer Inst VL - 105 UR - https://doi.org/10.1093/jnci/djs629 DO - 10.1093/jnci/djs629 ID - Formenti2013 ER - TY - JOUR AU - Twyman-Saint Victor, C. AU - Rech, A. J. AU - Maity, A. AU - Rengan, R. AU - Pauken, K. E. AU - Stelekati, E. PY - 2015 DA - 2015// TI - Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer JO - Nature VL - 520 UR - https://doi.org/10.1038/nature14292 DO - 10.1038/nature14292 ID - Twyman-Saint Victor2015 ER - TY - JOUR AU - Daly, M. E. AU - Monjazeb, A. M. AU - Kelly, K. PY - 2015 DA - 2015// TI - Clinical trials integrating immunotherapy and radiation for non-small-cell lung cancer JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000686 DO - 10.1097/JTO.0000000000000686 ID - Daly2015 ER - TY - JOUR AU - Ramakrishnan, R. AU - Assudani, D. AU - Nagaraj, S. AU - Hunter, T. AU - Cho, H. I. AU - Antonia, S. PY - 2010 DA - 2010// TI - Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice JO - J Clin Invest VL - 120 UR - https://doi.org/10.1172/JCI40269 DO - 10.1172/JCI40269 ID - Ramakrishnan2010 ER - TY - JOUR AU - Zitvogel, L. AU - Galluzzi, L. AU - Smyth, M. J. AU - Kroemer, G. PY - 2013 DA - 2013// TI - Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance JO - Immunity VL - 39 UR - https://doi.org/10.1016/j.immuni.2013.06.014 DO - 10.1016/j.immuni.2013.06.014 ID - Zitvogel2013 ER - TY - JOUR AU - Ma, Y. AU - Adjemian, S. AU - Mattarollo, S. R. AU - Yamazaki, T. AU - Aymeric, L. AU - Yang, H. PY - 2013 DA - 2013// TI - Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells JO - Immunity VL - 38 UR - https://doi.org/10.1016/j.immuni.2013.03.003 DO - 10.1016/j.immuni.2013.03.003 ID - Ma2013 ER - TY - JOUR AU - Vincent, J. AU - Mignot, G. AU - Chalmin, F. AU - Ladoire, S. AU - Bruchard, M. AU - Chevriaux, A. PY - 2010 DA - 2010// TI - 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3690 DO - 10.1158/0008-5472.CAN-09-3690 ID - Vincent2010 ER - TY - JOUR AU - Kanterman, J. AU - Sade-Feldman, M. AU - Biton, M. AU - Ish-Shalom, E. AU - Lasry, A. AU - Goldshtein, A. PY - 2014 DA - 2014// TI - Adverse immunoregulatory effects of 5FU and CPT11 chemotherapy on myeloid-derived suppressor cells and colorectal cancer outcomes JO - Cancer Res VL - 74 UR - https://doi.org/10.1158/0008-5472.CAN-14-0657 DO - 10.1158/0008-5472.CAN-14-0657 ID - Kanterman2014 ER - TY - JOUR AU - Butte, M. J. AU - Keir, M. E. AU - Phamduy, T. B. AU - Sharpe, A. H. AU - Freeman, G. J. PY - 2007 DA - 2007// TI - Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses JO - Immunity VL - 27 UR - https://doi.org/10.1016/j.immuni.2007.05.016 DO - 10.1016/j.immuni.2007.05.016 ID - Butte2007 ER - TY - JOUR AU - Benson, D. M. AU - Bakan, C. E. AU - Mishra, A. AU - Hofmeister, C. C. AU - Efebera, Y. AU - Becknell, B. PY - 2010 DA - 2010// TI - The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody JO - Blood VL - 116 UR - https://doi.org/10.1182/blood-2010-02-271874 DO - 10.1182/blood-2010-02-271874 ID - Benson2010 ER - TY - JOUR AU - Iwai, Y. AU - Ishida, M. AU - Tanaka, Y. AU - Okazaki, T. AU - Honjo, T. AU - Minato, N. PY - 2002 DA - 2002// TI - Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade JO - Proc Natl Acad Sci U S A VL - 99 UR - https://doi.org/10.1073/pnas.192461099 DO - 10.1073/pnas.192461099 ID - Iwai2002 ER - TY - JOUR AU - Liu, J. AU - Hamrouni, A. AU - Wolowiec, D. AU - Coiteux, V. AU - Kuliczkowski, K. AU - Hetuin, D. PY - 2007 DA - 2007// TI - Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2006-10-051482 DO - 10.1182/blood-2006-10-051482 ID - Liu2007 ER - TY - JOUR AU - Topalian, S. L. AU - Drake, C. G. AU - Pardoll, D. M. PY - 2015 DA - 2015// TI - Immune checkpoint blockade: a common denominator approach to cancer therapy JO - Cancer Cell VL - 27 UR - https://doi.org/10.1016/j.ccell.2015.03.001 DO - 10.1016/j.ccell.2015.03.001 ID - Topalian2015 ER - TY - JOUR AU - Skoulidis, F. AU - Byers, L. A. AU - Diao, L. AU - Papadimitrakopoulou, V. A. AU - Tong, P. AU - Izzo, J. PY - 2015 DA - 2015// TI - Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-14-1236 DO - 10.1158/2159-8290.CD-14-1236 ID - Skoulidis2015 ER - TY - JOUR AU - Chen, N. AU - Fang, W. AU - Zhan, J. AU - Hong, S. AU - Tang, Y. AU - Kang, S. PY - 2015 DA - 2015// TI - Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000500 DO - 10.1097/JTO.0000000000000500 ID - Chen2015 ER - TY - JOUR AU - Azuma, K. AU - Ota, K. AU - Kawahara, A. AU - Hattori, S. AU - Iwama, E. AU - Harada, T. PY - 2014 DA - 2014// TI - Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu242 DO - 10.1093/annonc/mdu242 ID - Azuma2014 ER - TY - JOUR AU - Ota, K. AU - Azuma, K. AU - Kawahara, A. AU - Hattori, S. AU - Iwama, E. AU - Tanizaki, J. PY - 2015 DA - 2015// TI - Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer JO - Clin Cancer Res VL - 21 UR - https://doi.org/10.1158/1078-0432.CCR-15-0016 DO - 10.1158/1078-0432.CCR-15-0016 ID - Ota2015 ER - TY - JOUR AU - Lastwika, K. J. AU - Wilson, W. AU - Li, Q. K. AU - Norris, J. AU - Xu, H. AU - Ghazarian, S. R. PY - 2016 DA - 2016// TI - Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer JO - Cancer Res VL - 76 UR - https://doi.org/10.1158/0008-5472.CAN-14-3362 DO - 10.1158/0008-5472.CAN-14-3362 ID - Lastwika2016 ER - TY - STD TI - Lou Y, Diao L, Parra Cuentas ER, Denning WL, Chen L, Fan YH, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res. 2016. doi:10.1158/1078-0432.CCR-15-1434. ID - ref49 ER - TY - JOUR AU - Ribas, A. PY - 2015 DA - 2015// TI - Adaptive immune resistance: how cancer protects from immune attack JO - Cancer Discov VL - 5 UR - https://doi.org/10.1158/2159-8290.CD-15-0563 DO - 10.1158/2159-8290.CD-15-0563 ID - Ribas2015 ER - TY - JOUR AU - Spranger, S. AU - Koblish, H. K. AU - Horton, B. AU - Scherle, P. A. AU - Newton, R. AU - Gajewski, T. F. PY - 2014 DA - 2014// TI - Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment JO - J Immunother Cancer VL - 2 UR - https://doi.org/10.1186/2051-1426-2-3 DO - 10.1186/2051-1426-2-3 ID - Spranger2014 ER - TY - JOUR AU - Gatalica, Z. AU - Snyder, C. AU - Maney, T. AU - Ghazalpour, A. AU - Holterman, D. A. AU - Xiao, N. PY - 2014 DA - 2014// TI - Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type JO - Cancer Epidemiol Biomarkers Prev VL - 23 UR - https://doi.org/10.1158/1055-9965.EPI-14-0654 DO - 10.1158/1055-9965.EPI-14-0654 ID - Gatalica2014 ER - TY - JOUR AU - Okiyama, N. AU - Katz, S. I. PY - 2014 DA - 2014// TI - Programmed cell death 1 (PD-1) regulates the effector function of CD8 T cells via PD-L1 expressed on target keratinocytes JO - J Autoimmun VL - 53 UR - https://doi.org/10.1016/j.jaut.2014.06.005 DO - 10.1016/j.jaut.2014.06.005 ID - Okiyama2014 ER - TY - JOUR AU - Hino, R. AU - Kabashima, K. AU - Kato, Y. AU - Yagi, H. AU - Nakamura, M. AU - Honjo, T. PY - 2010 DA - 2010// TI - Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma JO - Cancer VL - 116 UR - https://doi.org/10.1002/cncr.24899 DO - 10.1002/cncr.24899 ID - Hino2010 ER - TY - JOUR AU - Blackburn, S. D. AU - Shin, H. AU - Haining, W. N. AU - Zou, T. AU - Workman, C. J. AU - Polley, A. PY - 2009 DA - 2009// TI - Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection JO - Nat Immunol VL - 10 UR - https://doi.org/10.1038/ni.1679 DO - 10.1038/ni.1679 ID - Blackburn2009 ER - TY - JOUR AU - Nishimura, H. AU - Nose, M. AU - Hiai, H. AU - Minato, N. AU - Honjo, T. PY - 1999 DA - 1999// TI - Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor JO - Immunity VL - 11 UR - https://doi.org/10.1016/S1074-7613(00)80089-8 DO - 10.1016/S1074-7613(00)80089-8 ID - Nishimura1999 ER - TY - JOUR AU - Nishimura, H. AU - Okazaki, T. AU - Tanaka, Y. AU - Nakatani, K. AU - Hara, M. AU - Matsumori, A. PY - 2001 DA - 2001// TI - Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice JO - Science VL - 291 UR - https://doi.org/10.1126/science.291.5502.319 DO - 10.1126/science.291.5502.319 ID - Nishimura2001 ER - TY - JOUR AU - Curiel, T. J. AU - Wei, S. AU - Dong, H. AU - Alvarez, X. AU - Cheng, P. AU - Mottram, P. PY - 2003 DA - 2003// TI - Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity JO - Nat Med VL - 9 UR - https://doi.org/10.1038/nm863 DO - 10.1038/nm863 ID - Curiel2003 ER - TY - JOUR AU - Hirano, F. AU - Kaneko, K. AU - Tamura, H. AU - Dong, H. AU - Wang, S. AU - Ichikawa, M. PY - 2005 DA - 2005// TI - Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity JO - Cancer Res VL - 65 ID - Hirano2005 ER - TY - JOUR AU - Curran, M. A. AU - Montalvo, W. AU - Yagita, H. AU - Allison, J. P. PY - 2010 DA - 2010// TI - PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0915174107 DO - 10.1073/pnas.0915174107 ID - Curran2010 ER - TY - JOUR AU - Woo, S. R. AU - Turnis, M. E. AU - Goldberg, M. V. AU - Bankoti, J. AU - Selby, M. AU - Nirschl, C. J. PY - 2012 DA - 2012// TI - Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-1620 DO - 10.1158/0008-5472.CAN-11-1620 ID - Woo2012 ER - TY - JOUR AU - Tsai, K. K. AU - Daud, A. I. PY - 2015 DA - 2015// TI - Nivolumab plus ipilimumab in the treatment of advanced melanoma JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0219-0 DO - 10.1186/s13045-015-0219-0 ID - Tsai2015 ER - TY - JOUR AU - Massi, D. AU - Brusa, D. AU - Merelli, B. AU - Ciano, M. AU - Audrito, V. AU - Serra, S. PY - 2014 DA - 2014// TI - PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu452 DO - 10.1093/annonc/mdu452 ID - Massi2014 ER - TY - JOUR AU - Wong, R. M. AU - Scotland, R. R. AU - Lau, R. L. AU - Wang, C. AU - Korman, A. J. AU - Kast, W. M. PY - 2007 DA - 2007// TI - Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs JO - Int Immunol VL - 19 UR - https://doi.org/10.1093/intimm/dxm091 DO - 10.1093/intimm/dxm091 ID - Wong2007 ER - TY - JOUR AU - Wang, W. AU - Lau, R. AU - Yu, D. AU - Zhu, W. AU - Korman, A. AU - Weber, J. PY - 2009 DA - 2009// TI - PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells JO - Int Immunol VL - 21 UR - https://doi.org/10.1093/intimm/dxp072 DO - 10.1093/intimm/dxp072 ID - Wang2009 ER - TY - JOUR AU - Charlton, J. J. AU - Chatzidakis, I. AU - Tsoukatou, D. AU - Boumpas, D. T. AU - Garinis, G. A. AU - Mamalaki, C. PY - 2013 DA - 2013// TI - Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner JO - J Immunol VL - 190 UR - https://doi.org/10.4049/jimmunol.1201617 DO - 10.4049/jimmunol.1201617 ID - Charlton2013 ER - TY - JOUR AU - Topalian, S. L. AU - Sznol, M. AU - McDermott, D. F. AU - Kluger, H. M. AU - Carvajal, R. D. AU - Sharfman, W. H. PY - 2014 DA - 2014// TI - Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab JO - J Clin Oncol VL - 32 UR - https://doi.org/10.1200/JCO.2013.53.0105 DO - 10.1200/JCO.2013.53.0105 ID - Topalian2014 ER - TY - BOOK PY - 2015 DA - 2015// TI - FDA approves KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 with disease progression on or after platinum-containing chemotherapy ID - ref68 ER - TY - JOUR AU - Fox, B. A. AU - Schendel, D. J. AU - Butterfield, L. H. AU - Aamdal, S. AU - Allison, J. P. AU - Ascierto, P. A. PY - 2011 DA - 2011// TI - Defining the critical hurdles in cancer immunotherapy JO - J Transl Med VL - 9 UR - https://doi.org/10.1186/1479-5876-9-214 DO - 10.1186/1479-5876-9-214 ID - Fox2011 ER - TY - JOUR AU - Butterfield, L. H. AU - Disis, M. L. AU - Khleif, S. N. AU - Balwit, J. M. AU - Marincola, F. M. PY - 2010 DA - 2010// TI - Immuno-oncology biomarkers 2010 and beyond: perspectives from the iSBTc/SITC biomarker task force JO - J Transl Med VL - 8 UR - https://doi.org/10.1186/1479-5876-8-130 DO - 10.1186/1479-5876-8-130 ID - Butterfield2010 ER - TY - JOUR AU - Bedognetti, D. AU - Balwit, J. M. AU - Wang, E. AU - Disis, M. L. AU - Britten, C. M. AU - Delogu, L. G. PY - 2011 DA - 2011// TI - SITC/iSBTc cancer immunotherapy biomarkers resource document: online resources and useful tools—a compass in the land of biomarker discovery JO - J Transl Med VL - 9 UR - https://doi.org/10.1186/1479-5876-9-155 DO - 10.1186/1479-5876-9-155 ID - Bedognetti2011 ER - TY - JOUR AU - Yuan, J. AU - Hegde, P. S. AU - Clynes, R. AU - Foukas, P. G. AU - Harari, A. AU - Kleen, T. O. PY - 2016 DA - 2016// TI - Novel technologies and emerging biomarkers for personalized cancer immunotherapy JO - J Immunother Cancer VL - 4 UR - https://doi.org/10.1186/s40425-016-0107-3 DO - 10.1186/s40425-016-0107-3 ID - Yuan2016 ER - TY - JOUR AU - Hansen, A. R. AU - Siu, L. L. PY - 2016 DA - 2016// TI - PD-L1 testing in cancer: challenges in companion diagnostic development JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2015.4685 DO - 10.1001/jamaoncol.2015.4685 ID - Hansen2016 ER - TY - CHAP AU - Ratcliffe, M. J. AU - Sharpe, A. AU - Midha, A. AU - Barker, C. AU - Scorer, P. AU - Walker, J. PY - 2016 DA - 2016// TI - A comparative study of PD-L1 diagnostic assays and the classification of patients at PD-L1 positive and PD-L1 negative [abstract] BT - Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20 PB - AACR CY - New Orleans, LA Philadelphia (PA) ID - Ratcliffe2016 ER - TY - JOUR AU - Gandini, S. AU - Massi, D. AU - Mandala, M. PY - 2016 DA - 2016// TI - PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: a systematic review and meta-analysis JO - Crit Rev Oncol Hematol VL - 100 UR - https://doi.org/10.1016/j.critrevonc.2016.02.001 DO - 10.1016/j.critrevonc.2016.02.001 ID - Gandini2016 ER - TY - JOUR AU - Leffers, N. AU - Gooden, M. J. AU - Jong, R. A. AU - Hoogeboom, B. N. AU - Hoor, K. A. AU - Hollema, H. PY - 2009 DA - 2009// TI - Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer JO - Cancer Immunol Immunother VL - 58 UR - https://doi.org/10.1007/s00262-008-0583-5 DO - 10.1007/s00262-008-0583-5 ID - Leffers2009 ER - TY - JOUR AU - Hwang, W. T. AU - Adams, S. F. AU - Tahirovic, E. AU - Hagemann, I. S. AU - Coukos, G. PY - 2012 DA - 2012// TI - Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis JO - Gynecol Oncol VL - 124 UR - https://doi.org/10.1016/j.ygyno.2011.09.039 DO - 10.1016/j.ygyno.2011.09.039 ID - Hwang2012 ER - TY - JOUR AU - Erdag, G. AU - Schaefer, J. T. AU - Smolkin, M. E. AU - Deacon, D. H. AU - Shea, S. M. AU - Dengel, L. T. PY - 2012 DA - 2012// TI - Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma JO - Cancer Res VL - 72 UR - https://doi.org/10.1158/0008-5472.CAN-11-3218 DO - 10.1158/0008-5472.CAN-11-3218 ID - Erdag2012 ER - TY - JOUR AU - Feng, Z. AU - Puri, S. AU - Moudgil, T. AU - Wood, W. AU - Hoyt, C. C. AU - Wang, C. PY - 2015 DA - 2015// TI - Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/s40425-015-0091-z DO - 10.1186/s40425-015-0091-z ID - Feng2015 ER - TY - JOUR AU - Stack, E. C. AU - Wang, C. AU - Roman, K. A. AU - Hoyt, C. C. PY - 2014 DA - 2014// TI - Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis JO - Methods VL - 70 UR - https://doi.org/10.1016/j.ymeth.2014.08.016 DO - 10.1016/j.ymeth.2014.08.016 ID - Stack2014 ER - TY - JOUR AU - Ichihara, F. AU - Kono, K. AU - Takahashi, A. AU - Kawaida, H. AU - Sugai, H. AU - Fujii, H. PY - 2003 DA - 2003// TI - Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers JO - Clin Cancer Res VL - 9 ID - Ichihara2003 ER - TY - STD TI - Basu S, Campbell HM, Dittel BN, Ray A. Purification of specific cell population by fluorescence activated cell sorting (FACS). J Vis Exp. 2010(41): e1546. doi:10.3791/1546. ID - ref82 ER - TY - JOUR AU - Zaritskaya, L. AU - Shurin, M. R. AU - Sayers, T. J. AU - Malyguine, A. M. PY - 2010 DA - 2010// TI - New flow cytometric assays for monitoring cell-mediated cytotoxicity JO - Expert Rev Vaccines VL - 9 UR - https://doi.org/10.1586/erv.10.49 DO - 10.1586/erv.10.49 ID - Zaritskaya2010 ER - TY - JOUR AU - Yuan, J. AU - Gnjatic, S. AU - Li, H. AU - Powel, S. AU - Gallardo, H. F. AU - Ritter, E. PY - 2008 DA - 2008// TI - CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit JO - Proc Natl Acad Sci U S A VL - 105 UR - https://doi.org/10.1073/pnas.0810114105 DO - 10.1073/pnas.0810114105 ID - Yuan2008 ER - TY - JOUR AU - Attig, S. AU - Price, L. AU - Janetzki, S. AU - Kalos, M. AU - Pride, M. AU - McNeil, L. PY - 2011 DA - 2011// TI - A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols JO - J Transl Med VL - 9 UR - https://doi.org/10.1186/1479-5876-9-108 DO - 10.1186/1479-5876-9-108 ID - Attig2011 ER - TY - JOUR AU - McNeil, L. K. AU - Price, L. AU - Britten, C. M. AU - Jaimes, M. AU - Maecker, H. AU - Odunsi, K. PY - 2013 DA - 2013// TI - A harmonized approach to intracellular cytokine staining gating: results from an international multiconsortia proficiency panel conducted by the cancer immunotherapy consortium (CIC/CRI) JO - Cytometry A VL - 83 UR - https://doi.org/10.1002/cyto.a.22319 DO - 10.1002/cyto.a.22319 ID - McNeil2013 ER - TY - JOUR AU - Vales-Gomez, M. AU - Reyburn, H. T. AU - Erskine, R. A. AU - Lopez-Botet, M. AU - Strominger, J. L. PY - 1999 DA - 1999// TI - Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E JO - EMBO J VL - 18 UR - https://doi.org/10.1093/emboj/18.15.4250 DO - 10.1093/emboj/18.15.4250 ID - Vales-Gomez1999 ER - TY - JOUR AU - Maecker, H. T. AU - Harari, A. PY - 2015 DA - 2015// TI - Immune monitoring technology primer: flow and mass cytometry JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/s40425-015-0085-x DO - 10.1186/s40425-015-0085-x ID - Maecker2015 ER - TY - JOUR AU - Kerr, K. M. AU - Tsao, M. S. AU - Nicholson, A. G. AU - Yatabe, Y. AU - Wistuba, I. I. AU - Hirsch, F. R. PY - 2015 DA - 2015// TI - Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art? JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000526 DO - 10.1097/JTO.0000000000000526 ID - Kerr2015 ER - TY - JOUR AU - Gnjatic, S. AU - Ritter, E. AU - Buchler, M. W. AU - Giese, N. A. AU - Brors, B. AU - Frei, C. PY - 2010 DA - 2010// TI - Seromic profiling of ovarian and pancreatic cancer JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0914213107 DO - 10.1073/pnas.0914213107 ID - Gnjatic2010 ER - TY - JOUR AU - Yuan, J. AU - Wang, E. AU - Fox, B. A. PY - 2016 DA - 2016// TI - Immune monitoring technology primer: protein microarray (‘seromics’) JO - J Immunother Cancer VL - 4 UR - https://doi.org/10.1186/s40425-016-0106-4 DO - 10.1186/s40425-016-0106-4 ID - Yuan2016 ER - TY - BOOK PY - 2015 DA - 2015// TI - General information, technology overview, and applications using the ProtoArray® Human Protein Microarray. ProtoArray® Applications Guide ID - ref92 ER - TY - JOUR AU - Janetzki, S. AU - Price, L. AU - Schroeder, H. AU - Britten, C. M. AU - Welters, M. J. AU - Hoos, A. PY - 2015 DA - 2015// TI - Guidelines for the automated evaluation of Elispot assays JO - Nat Protoc VL - 10 UR - https://doi.org/10.1038/nprot.2015.068 DO - 10.1038/nprot.2015.068 ID - Janetzki2015 ER - TY - JOUR AU - Malyguine, A. M. AU - Strobl, S. AU - Dunham, K. AU - Shurin, M. R. AU - Sayers, T. J. PY - 2012 DA - 2012// TI - ELISPOT assay for monitoring cytotoxic T lymphocytes (CTL) activity in cancer vaccine clinical trials JO - Cells VL - 1 UR - https://doi.org/10.3390/cells1020111 DO - 10.3390/cells1020111 ID - Malyguine2012 ER - TY - JOUR AU - Janetzki, S. AU - Panageas, K. S. AU - Ben-Porat, L. AU - Boyer, J. AU - Britten, C. M. AU - Clay, T. M. PY - 2008 DA - 2008// TI - Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the cancer vaccine consortium (CVC/SVI) JO - Cancer Immunol Immunother VL - 57 UR - https://doi.org/10.1007/s00262-007-0380-6 DO - 10.1007/s00262-007-0380-6 ID - Janetzki2008 ER - TY - JOUR AU - Butterfield, L. H. AU - Buffo, M. J. PY - 2014 DA - 2014// TI - Immunologic monitoring of cancer vaccine trials using the ELISPOT assay JO - Methods Mol Biol VL - 1102 UR - https://doi.org/10.1007/978-1-62703-727-3_5 DO - 10.1007/978-1-62703-727-3_5 ID - Butterfield2014 ER - TY - JOUR AU - Gabrielsson, S. AU - Brichard, V. AU - Dhellin, O. AU - Dorval, T. AU - Bonnerot, C. PY - 2004 DA - 2004// TI - IFN-gamma responses in peptide-treated melanoma patients measured by an ELISPOT assay using allogeneic dendritic cells JO - Anticancer Res VL - 24 ID - Gabrielsson2004 ER - TY - JOUR AU - Scheibenbogen, C. AU - Lee, K. H. AU - Stevanovic, S. AU - Witzens, M. AU - Willhauck, M. AU - Waldmann, V. PY - 1997 DA - 1997// TI - Analysis of the T cell response to tumor and viral peptide antigens by an IFNgamma-ELISPOT assay JO - Int J Cancer VL - 71 UR - https://doi.org/3.0.CO;2-Z DO - 3.0.CO;2-Z ID - Scheibenbogen1997 ER - TY - JOUR AU - Janetzki, S. PY - 2015 DA - 2015// TI - Immune monitoring technology primer: the enzyme-linked immunospot (Elispot) and fluorospot assay JO - J Immunother Cancer VL - 3 UR - https://doi.org/10.1186/s40425-015-0074-0 DO - 10.1186/s40425-015-0074-0 ID - Janetzki2015 ER - TY - JOUR AU - Robins, H. S. AU - Ericson, N. G. AU - Guenthoer, J. AU - O'Briant, K. C. AU - Tewari, M. AU - Drescher, C. W. PY - 2013 DA - 2013// TI - Digital genomic quantification of tumor-infiltrating lymphocytes JO - Sci Transl Med VL - 5 UR - https://doi.org/10.1126/scitranslmed.3007247 DO - 10.1126/scitranslmed.3007247 ID - Robins2013 ER - TY - JOUR AU - Cha, E. AU - Klinger, M. AU - Hou, Y. AU - Cummings, C. AU - Ribas, A. AU - Faham, M. PY - 2014 DA - 2014// TI - Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients JO - Sci Transl Med VL - 6 UR - https://doi.org/10.1126/scitranslmed.3008211 DO - 10.1126/scitranslmed.3008211 ID - Cha2014 ER - TY - JOUR AU - Schumacher, T. N. AU - Schreiber, R. D. PY - 2015 DA - 2015// TI - Neoantigens in cancer immunotherapy JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa4971 DO - 10.1126/science.aaa4971 ID - Schumacher2015 ER - TY - JOUR AU - Gubin, M. M. AU - Artyomov, M. N. AU - Mardis, E. R. AU - Schreiber, R. D. PY - 2015 DA - 2015// TI - Tumor neoantigens: building a framework for personalized cancer immunotherapy JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80008 DO - 10.1172/JCI80008 ID - Gubin2015 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. AU - Yuan, J. AU - Zaretsky, J. M. AU - Desrichard, A. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. AU - Kvistborg, P. AU - Makarov, V. AU - Havel, J. J. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. AU - Song, C. AU - Moreno, B. H. AU - Hu-Lieskovan, S. PY - 2016 DA - 2016// TI - Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell VL - 165 UR - https://doi.org/10.1016/j.cell.2016.02.065 DO - 10.1016/j.cell.2016.02.065 ID - Hugo2016 ER - TY - STD TI - Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, et al. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol. 2016. doi: 10.1200/JCO.2016.66.6552. ID - ref107 ER - TY - JOUR AU - Hoffmann, S. AU - Cepok, S. AU - Grummel, V. AU - Lehmann-Horn, K. AU - Hackermuller, J. AU - Stadler, P. F. PY - 2008 DA - 2008// TI - HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with the development of antibodies against interferon-beta therapy in multiple sclerosis JO - Am J Hum Genet VL - 83 UR - https://doi.org/10.1016/j.ajhg.2008.07.006 DO - 10.1016/j.ajhg.2008.07.006 ID - Hoffmann2008 ER - TY - JOUR AU - International Multiple Sclerosis Genetics, C. AU - Wellcome Trust Case Control, C. AU - Sawcer, S. AU - Hellenthal, G. AU - Pirinen, M. AU - Spencer, C. C. PY - 2011 DA - 2011// TI - Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis JO - Nature VL - 476 UR - https://doi.org/10.1038/nature10251 DO - 10.1038/nature10251 ID - International Multiple Sclerosis Genetics2011 ER - TY - JOUR AU - Konishi, J. AU - Yamazaki, K. AU - Azuma, M. AU - Kinoshita, I. AU - Dosaka-Akita, H. AU - Nishimura, M. PY - 2004 DA - 2004// TI - B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression JO - Clin Cancer Res VL - 10 UR - https://doi.org/10.1158/1078-0432.CCR-04-0428 DO - 10.1158/1078-0432.CCR-04-0428 ID - Konishi2004 ER - TY - JOUR AU - Chen, Y. Y. AU - Wang, L. B. AU - Zhu, H. L. AU - Li, X. Y. AU - Zhu, Y. P. AU - Yin, Y. L. PY - 2013 DA - 2013// TI - Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients JO - Chin Med Sci J VL - 28 UR - https://doi.org/10.1016/S1001-9294(13)60040-1 DO - 10.1016/S1001-9294(13)60040-1 ID - Chen2013 ER - TY - JOUR AU - Massi, D. AU - Brusa, D. AU - Merelli, B. AU - Falcone, C. AU - Xue, G. AU - Carobbio, A. PY - 2015 DA - 2015// TI - The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv255 DO - 10.1093/annonc/mdv255 ID - Massi2015 ER - TY - JOUR AU - Taube, J. M. AU - Klein, A. AU - Brahmer, J. R. AU - Xu, H. AU - Pan, X. AU - Kim, J. H. PY - 2014 DA - 2014// TI - Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-3271 DO - 10.1158/1078-0432.CCR-13-3271 ID - Taube2014 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. AU - Bartlett, B. R. AU - Kemberling, H. AU - Eyring, A. D. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Tran, E. AU - Ahmadzadeh, M. AU - Lu, Y. C. AU - Gros, A. AU - Turcotte, S. AU - Robbins, P. F. PY - 2015 DA - 2015// TI - Immunogenicity of somatic mutations in human gastrointestinal cancers JO - Science VL - 350 UR - https://doi.org/10.1126/science.aad1253 DO - 10.1126/science.aad1253 ID - Tran2015 ER - TY - JOUR AU - Lin, A. Y. AU - Lin, E. PY - 2015 DA - 2015// TI - Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors? JO - J Hematol Oncol VL - 8 UR - https://doi.org/10.1186/s13045-015-0222-5 DO - 10.1186/s13045-015-0222-5 ID - Lin2015 ER - TY - JOUR AU - Robbins, P. F. AU - Lu, Y. C. AU - El-Gamil, M. AU - Li, Y. F. AU - Gross, C. AU - Gartner, J. PY - 2013 DA - 2013// TI - Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells JO - Nat Med VL - 19 UR - https://doi.org/10.1038/nm.3161 DO - 10.1038/nm.3161 ID - Robbins2013 ER - TY - JOUR AU - Gros, A. AU - Parkhurst, M. R. AU - Tran, E. AU - Pasetto, A. AU - Robbins, P. F. AU - Ilyas, S. PY - 2016 DA - 2016// TI - Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients JO - Nat Med VL - 22 UR - https://doi.org/10.1038/nm.4051 DO - 10.1038/nm.4051 ID - Gros2016 ER - TY - JOUR AU - Velcheti, V. AU - Schalper, K. A. AU - Carvajal, D. E. AU - Anagnostou, V. K. AU - Syrigos, K. N. AU - Sznol, M. PY - 2014 DA - 2014// TI - Programmed death ligand-1 expression in non-small cell lung cancer JO - Lab Invest VL - 94 UR - https://doi.org/10.1038/labinvest.2013.130 DO - 10.1038/labinvest.2013.130 ID - Velcheti2014 ER - TY - JOUR AU - Ahmadzadeh, M. AU - Johnson, L. A. AU - Heemskerk, B. AU - Wunderlich, J. R. AU - Dudley, M. E. AU - White, D. E. PY - 2009 DA - 2009// TI - Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2008-12-195792 DO - 10.1182/blood-2008-12-195792 ID - Ahmadzadeh2009 ER - TY - JOUR AU - Tumeh, P. C. AU - Harview, C. L. AU - Yearley, J. H. AU - Shintaku, I. P. AU - Taylor, E. J. AU - Robert, L. PY - 2014 DA - 2014// TI - PD-1 blockade induces responses by inhibiting adaptive immune resistance JO - Nature VL - 515 UR - https://doi.org/10.1038/nature13954 DO - 10.1038/nature13954 ID - Tumeh2014 ER - TY - JOUR AU - Yung, S. AU - Ledran, M. AU - Moreno-Gimeno, I. AU - Conesa, A. AU - Montaner, D. AU - Dopazo, J. PY - 2011 DA - 2011// TI - Large-scale transcriptional profiling and functional assays reveal important roles for Rho-GTPase signalling and SCL during haematopoietic differentiation of human embryonic stem cells JO - Hum Mol Genet VL - 20 UR - https://doi.org/10.1093/hmg/ddr431 DO - 10.1093/hmg/ddr431 ID - Yung2011 ER - TY - JOUR AU - Galon, J. AU - Mlecnik, B. AU - Bindea, G. AU - Angell, H. K. AU - Berger, A. AU - Lagorce, C. PY - 2014 DA - 2014// TI - Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours JO - J Pathol VL - 232 UR - https://doi.org/10.1002/path.4287 DO - 10.1002/path.4287 ID - Galon2014 ER - TY - JOUR AU - Shay, T. AU - Jojic, V. AU - Zuk, O. AU - Rothamel, K. AU - Puyraimond-Zemmour, D. AU - Feng, T. PY - 2013 DA - 2013// TI - Conservation and divergence in the transcriptional programs of the human and mouse immune systems JO - Proc Natl Acad Sci U S A VL - 110 UR - https://doi.org/10.1073/pnas.1222738110 DO - 10.1073/pnas.1222738110 ID - Shay2013 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crino, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Weber, J. S. AU - D'Angelo, S. P. AU - Minor, D. AU - Hodi, F. S. AU - Gutzmer, R. AU - Neyns, B. PY - 2015 DA - 2015// TI - Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70076-8 DO - 10.1016/S1470-2045(15)70076-8 ID - Weber2015 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Larkin, J. AU - Chiarion-Sileni, V. AU - Gonzalez, R. AU - Grob, J. J. AU - Cowey, C. L. AU - Lao, C. D. PY - 2015 DA - 2015// TI - Combined nivolumab and ipilimumab or monotherapy in untreated melanoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504030 DO - 10.1056/NEJMoa1504030 ID - Larkin2015 ER - TY - JOUR AU - Rizvi, N. A. AU - Mazieres, J. AU - Planchard, D. AU - Stinchcombe, T. E. AU - Dy, G. K. AU - Antonia, S. J. PY - 2015 DA - 2015// TI - Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)70054-9 DO - 10.1016/S1470-2045(15)70054-9 ID - Rizvi2015 ER - TY - JOUR AU - McDermott, D. F. AU - Drake, C. G. AU - Sznol, M. AU - Choueiri, T. K. AU - Powderly, J. D. AU - Smith, D. C. PY - 2015 DA - 2015// TI - Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.1041 DO - 10.1200/JCO.2014.58.1041 ID - McDermott2015 ER - TY - JOUR AU - Gettinger, S. N. AU - Horn, L. AU - Gandhi, L. AU - Spigel, D. R. AU - Antonia, S. J. AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3708 DO - 10.1200/JCO.2014.58.3708 ID - Gettinger2015 ER - TY - JOUR AU - Robert, C. AU - Schachter, J. AU - Long, G. V. AU - Arance, A. AU - Grob, J. J. AU - Mortier, L. PY - 2015 DA - 2015// TI - Pembrolizumab versus ipilimumab in advanced melanoma JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1503093 DO - 10.1056/NEJMoa1503093 ID - Robert2015 ER - TY - JOUR AU - Ribas, A. AU - Puzanov, I. AU - Dummer, R. AU - Schadendorf, D. AU - Hamid, O. AU - Robert, C. PY - 2015 DA - 2015// TI - Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(15)00083-2 DO - 10.1016/S1470-2045(15)00083-2 ID - Ribas2015 ER - TY - JOUR AU - Daud, A. AU - Ribas, A. AU - Robert, C. AU - Hodi, F. S. AU - Wolchok, J. D. AU - Joshua, A. M. PY - 2015 DA - 2015// TI - Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001 JO - ASCO Meeting Abstr VL - 33 ID - Daud2015 ER - TY - JOUR AU - Ribas, A. AU - Hamid, O. AU - Daud, A. AU - Hodi, F. S. AU - Wolchok, J. D. AU - Kefford, R. PY - 2016 DA - 2016// TI - Association of pembrolizumab with tumor response and survival among patients with advanced melanoma JO - JAMA VL - 315 UR - https://doi.org/10.1001/jama.2016.4059 DO - 10.1001/jama.2016.4059 ID - Ribas2016 ER - TY - JOUR AU - Robert, C. AU - Ribas, A. AU - Wolchok, J. D. AU - Hodi, F. S. AU - Hamid, O. AU - Kefford, R. PY - 2014 DA - 2014// TI - Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial JO - Lancet VL - 384 UR - https://doi.org/10.1016/S0140-6736(14)60958-2 DO - 10.1016/S0140-6736(14)60958-2 ID - Robert2014 ER - TY - JOUR AU - Nanda, R. AU - Chow, L. Q. AU - Dees, E. C. AU - Berger, R. AU - Gupta, S. AU - Geva, R. PY - 2015 DA - 2015// TI - Abstract S1-09: a phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer JO - Cancer Res VL - 75 UR - https://doi.org/10.1158/1538-7445.SABCS14-S1-09 DO - 10.1158/1538-7445.SABCS14-S1-09 ID - Nanda2015 ER - TY - JOUR AU - Herbst, R. S. AU - Baas, P. AU - Kim, D. W. AU - Felip, E. AU - Perez-Gracia, J. L. AU - Han, J. Y. PY - 2015 DA - 2015// TI - Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(15)01281-7 DO - 10.1016/S0140-6736(15)01281-7 ID - Herbst2015 ER - TY - STD TI - Moskowitz C, Ribrag V, Michot J-M, Martinelli G, Zinzani PL, Gutierrez M, et al. PD-1 Blockade with the monoclonal antibody Pembrolizumab (M-3475) in patients with classical Hodgkin Lymphoma after Brentuximab Vedotin Failure: Preliminary results from a phase 1b study [abstract]. Blood. 2014;124:290. abstract. ID - ref141 ER - TY - JOUR AU - Spigel, D. R. AU - Chaft, J. E. AU - Gettinger, S. N. AU - Chao, B. H. AU - Dirix, L. Y. AU - Schmid, P. PY - 2015 DA - 2015// TI - Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) JO - ASCO Meeting Abstr VL - 33 ID - Spigel2015 ER - TY - JOUR AU - Spira, A. I. AU - Park, K. AU - Mazieres, J. AU - Vansteenkiste, J. F. AU - Rittmeyer, A. AU - Ballinger, M. PY - 2015 DA - 2015// TI - Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) JO - ASCO Meeting Abstr VL - 33 ID - Spira2015 ER - TY - JOUR AU - Hamid, O. AU - Sosman, J. A. AU - Lawrence, D. P. AU - Sullivan, R. J. AU - Ibrahim, N. AU - Kluger, H. M. PY - 2013 DA - 2013// TI - Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM) JO - ASCO Meeting Abstr VL - 31 ID - Hamid2013 ER - TY - JOUR AU - Herbst, R. S. AU - Soria, J. C. AU - Kowanetz, M. AU - Fine, G. D. AU - Hamid, O. AU - Gordon, M. S. PY - 2014 DA - 2014// TI - Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients JO - Nature VL - 515 UR - https://doi.org/10.1038/nature14011 DO - 10.1038/nature14011 ID - Herbst2014 ER - TY - JOUR AU - Liu, S. V. AU - Powderly, J. D. AU - Camidge, D. R. AU - Ready, N. AU - Heist, R. S. AU - Hodi, F. S. PY - 2015 DA - 2015// TI - Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) JO - ASCO Meeting Abstr VL - 33 ID - Liu2015 ER - TY - JOUR AU - Bendell, J. C. AU - Powderly, J. D. AU - Lieu, C. H. AU - Eckhardt, S. G. AU - Hurwitz, H. AU - Hochster, H. S. PY - 2015 DA - 2015// TI - Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC) JO - ASCO Meeting Abstr VL - 33 ID - Bendell2015 ER - TY - JOUR AU - Sznol, M. AU - McDermott, D. F. AU - Jones, S. F. AU - Mier, J. W. AU - Waterkamp, D. AU - Rossi, C. PY - 2015 DA - 2015// TI - Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC) JO - ASCO Meeting Abstr VL - 33 ID - Sznol2015 ER - TY - JOUR AU - Rizvi, N. A. AU - Brahmer, J. R. AU - Ou, S. -. H. I. AU - Segal, N. H. AU - Khleif, S. AU - Hwu, W. -. J. PY - 2015 DA - 2015// TI - Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC) JO - ASCO Meeting Abstr VL - 33 ID - Rizvi2015 ER - TY - JOUR AU - Brahmer, J. R. AU - Rizvi, N. A. AU - Lutzky, J. AU - Khleif, S. AU - Blake-Haskins, A. AU - Li, X. PY - 2014 DA - 2014// TI - Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC JO - ASCO Meeting Abstr VL - 32 ID - Brahmer2014 ER - TY - JOUR AU - Segal, N. H. AU - Ou, S. -. H. I. AU - Balmanoukian, A. S. AU - Fury, M. G. AU - Massarelli, E. AU - Brahmer, J. R. PY - 2015 DA - 2015// TI - Safety and efficacy of MEDI4736, an anti-PD-L1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort JO - ASCO Meeting Abstr VL - 33 ID - Segal2015 ER - TY - JOUR AU - Lutzky, J. AU - Antonia, S. J. AU - Blake-Haskins, A. AU - Li, X. AU - Robbins, P. B. AU - Shalabi, A. M. PY - 2014 DA - 2014// TI - A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors JO - ASCO Meeting Abstr VL - 32 ID - Lutzky2014 ER - TY - JOUR AU - Creelan, B. C. AU - Chow, L. Q. AU - Kim, D. -. W. AU - Kim, S. -. W. AU - Yeh, T. AU - Karakunnel, J. J. PY - 2015 DA - 2015// TI - Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC) JO - ASCO Meeting Abstr VL - 33 ID - Creelan2015 ER - TY - JOUR AU - Antonia, S. J. AU - Goldberg, S. B. AU - Balmanoukian, A. S. AU - Sanborn, R. E. AU - Steele, K. AU - Narwal, R. PY - 2015 DA - 2015// TI - Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC JO - ASCO Meeting Abstr VL - 33 ID - Antonia2015 ER - TY - JOUR AU - Antonia, S. AU - Goldberg, S. B. AU - Balmanoukian, A. AU - Chaft, J. E. AU - Sanborn, R. E. AU - Gupta, A. PY - 2016 DA - 2016// TI - Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00544-6 DO - 10.1016/S1470-2045(15)00544-6 ID - Antonia2016 ER - TY - JOUR AU - Paz-Ares, L. AU - Horn, L. AU - Borghaei, H. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. PY - 2015 DA - 2015// TI - Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC) JO - ASCO Meeting Abstr VL - 33 ID - Paz-Ares2015 ER - TY - JOUR AU - Gettinger, S. N. AU - Hellmann, M. D. AU - Shepherd, F. A. AU - Antonia, S. J. AU - Brahmer, J. R. AU - Chow, L. Q. M. PY - 2015 DA - 2015// TI - First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression JO - ASCO Meeting Abstr VL - 33 ID - Gettinger2015 ER - TY - JOUR AU - Antonia, S. J. AU - Gettinger, S. N. AU - Chow, L. Q. M. AU - Juergens, R. A. AU - Borghaei, H. AU - Shen, Y. PY - 2014 DA - 2014// TI - Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results JO - ASCO Meeting Abstr VL - 32 ID - Antonia2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Garon, E. B. AU - Leighl, N. AU - Hellmann, M. D. AU - Patnaik, A. AU - Gandhi, L. PY - 2015 DA - 2015// TI - Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001 JO - ASCO Meeting Abstr VL - 33 ID - Rizvi2015 ER - TY - JOUR AU - Garon, E. B. AU - Gandhi, L. AU - Rizvi, N. AU - Hui, R. AU - Balmanoukian, A. S. AU - Patnaik, A. PY - 2014 DA - 2014// TI - Antitumor activity of pembrolizumab (pembro; mk-3475) and correlation with programmed death ligand 1 (pd-l1) expression in a pooled analysis of patients (pts) with advanced non–small cell lung carcinoma (NSCLC) JO - Ann Oncol VL - 25 ID - Garon2014 ER - TY - JOUR AU - Garon, E. B. AU - Leighl, N. B. AU - Rizvi, N. A. AU - Blumenschein, G. R. AU - Balmanoukian, A. S. AU - Eder, J. P. PY - 2014 DA - 2014// TI - Safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC) JO - ASCO Meeting Abstr VL - 32 ID - Garon2014 ER - TY - JOUR AU - Horn, L. AU - Spigel, D. R. AU - Gettinger, S. N. AU - Antonia, S. J. AU - Gordon, M. S. AU - Herbst, R. S. PY - 2015 DA - 2015// TI - Clinical activity, safety and predictive biomarkers of the engineered antibody MPDL3280A (anti-PDL1) in non-small cell lung cancer (NSCLC): update from a phase Ia study JO - ASCO Meeting Abstr VL - 33 ID - Horn2015 ER - TY - JOUR AU - Segal, N. H. AU - Antonia, S. J. AU - Brahmer, J. R. AU - Maio, M. AU - Blake-Haskins, A. AU - Li, X. PY - 2014 DA - 2014// TI - Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody JO - ASCO Meeting Abstr VL - 32 ID - Segal2014 ER - TY - JOUR AU - Loughlin, P. M. AU - Cooke, T. G. AU - George, W. D. AU - Gray, A. J. AU - Stott, D. I. AU - Going, J. J. PY - 2007 DA - 2007// TI - Quantifying tumour-infiltrating lymphocyte subsets: a practical immuno-histochemical method JO - J Immunol Methods VL - 321 UR - https://doi.org/10.1016/j.jim.2007.01.012 DO - 10.1016/j.jim.2007.01.012 ID - Loughlin2007 ER - TY - JOUR AU - Carvajal-Hausdorf, D. E. AU - Schalper, K. A. AU - Neumeister, V. M. AU - Rimm, D. L. PY - 2015 DA - 2015// TI - Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic JO - Lab Invest VL - 95 UR - https://doi.org/10.1038/labinvest.2014.157 DO - 10.1038/labinvest.2014.157 ID - Carvajal-Hausdorf2015 ER - TY - JOUR AU - Chen, K. H. AU - Yuan, C. T. AU - Tseng, L. H. AU - Shun, C. T. AU - Yeh, K. H. PY - 2016 DA - 2016// TI - Case report: mismatch repair proficiency and microsatellite stability in gastric cancer may not predict programmed death-1 blockade resistance JO - J Hematol Oncol VL - 9 UR - https://doi.org/10.1186/s13045-016-0259-0 DO - 10.1186/s13045-016-0259-0 ID - Chen2016 ER - TY - JOUR AU - Shafer-Weaver, K. AU - Rosenberg, S. AU - Strobl, S. AU - Gregory Alvord, W. AU - Baseler, M. AU - Malyguine, A. PY - 2006 DA - 2006// TI - Application of the granzyme B ELISPOT assay for monitoring cancer vaccine trials JO - J Immunother VL - 29 UR - https://doi.org/10.1097/01.cji.0000203079.35612.c8 DO - 10.1097/01.cji.0000203079.35612.c8 ID - Shafer-Weaver2006 ER - TY - JOUR AU - Barrera, L. AU - Rodriguez, O. A. AU - Morales-Flores, R. AU - Garcia-Vicente, A. AU - Servín, E. M. AU - Salinas-Parra, F. PY - 2015 DA - 2015// TI - MINI 02.03 over expression of CD47, decrease of apoptosis and phagocytosis of neutrophils in advanced non-small cell lung cancer patients JO - J Thoracic Oncol VL - 10 ID - Barrera2015 ER - TY - JOUR AU - Streitz, M. AU - Miloud, T. AU - Kapinsky, M. AU - Reed, M. R. AU - Magari, R. AU - Geissler, E. K. PY - 2013 DA - 2013// TI - Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study JO - Transplant Res VL - 2 UR - https://doi.org/10.1186/2047-1440-2-17 DO - 10.1186/2047-1440-2-17 ID - Streitz2013 ER - TY - JOUR AU - Dongen, J. J. AU - Lhermitte, L. AU - Bottcher, S. AU - Almeida, J. AU - Velden, V. H. AU - Flores-Montero, J. PY - 2012 DA - 2012// TI - EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2012.120 DO - 10.1038/leu.2012.120 ID - Dongen2012 ER - TY - JOUR AU - Zhao, S. AU - Fung-Leung, W. P. AU - Bittner, A. AU - Ngo, K. AU - Liu, X. PY - 2014 DA - 2014// TI - Comparison of RNA-Seq and microarray in transcriptome profiling of activated T cells JO - PLoS One VL - 9 UR - https://doi.org/10.1371/journal.pone.0078644 DO - 10.1371/journal.pone.0078644 ID - Zhao2014 ER - TY - JOUR AU - Kammula, U. S. AU - Serrano, O. K. PY - 2008 DA - 2008// TI - Use of high throughput qPCR screening to rapidly clone low frequency tumour specific T-cells from peripheral blood for adoptive immunotherapy JO - J Transl Med VL - 6 UR - https://doi.org/10.1186/1479-5876-6-60 DO - 10.1186/1479-5876-6-60 ID - Kammula2008 ER - TY - JOUR AU - Lin, S. H. AU - He, J. AU - Edelman, M. AU - Xu, T. AU - Gao, H. AU - Reuben, J. PY - 2015 DA - 2015// TI - MINI 02.04 sequential assessment of DNA damage response and PD-L1 expression in circulating cells of lung cancer patients during treatment with radiotherapy JO - J Thoracic Oncol VL - 10 ID - Lin2015 ER - TY - JOUR AU - Adams, D. L. AU - Martin, S. S. AU - Alpaugh, R. K. AU - Charpentier, M. AU - Tsai, S. AU - Bergan, R. C. PY - 2014 DA - 2014// TI - Circulating giant macrophages as a potential biomarker of solid tumors JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1320198111 DO - 10.1073/pnas.1320198111 ID - Adams2014 ER -